Literature DB >> 2033691

The prognostic value of deoxyribonucleic acid flow cytometric analysis in stage D2 prostatic carcinoma.

J Miller1, D J Horsfall, V R Marshall, D M Rao, S Y Leong.   

Abstract

This study was designed to compare the prognostic potential of tumor grade and ploidy status in patients with stage D2 prostate cancer. Two outcome groups were selected on the basis of survival after orchiectomy: a bad outcome group consisting of 66 patients who died of the disease within 12 months and a good outcome group comprising 37 patients who survived beyond 5 years. Tumors were classified histologically as well (17%), moderately (17%) or poorly (66%) differentiated. Tumor grade was a significant predictor of outcome, with 76% of poorly differentiated tumors in the bad outcome group and 65% of well differentiated tumors in the good outcome group (p less than 0.005). Deoxyribonucleic acid (DNA) ploidy analysis was performed on formalin fixed, paraffin embedded samples of the primary tumor to yield 97 final tracings that were classified using set criteria for DNA ploidy status. Over-all, 54% of the tumors were nondiploid (33% aneuploid and 21% tetraploid) and the remaining 46% were diploid. DNA ploidy status was a significant indicator of outcome (p less than 0.001), with 64% of diploid tumors in the good outcome group and 88% of the nondiploid tumors in the poor outcome group. Tetraploid tumors behaved no differently from other nondiploid tumors. We conclude that DNA ploidy status and tumor grading are significant independent predictors of outcome after orchiectomy and when combined yield important additional prognostic information.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2033691     DOI: 10.1016/s0022-5347(17)38572-5

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  3 in total

1.  DNA-ploidy, G2M-fractions and prognosis of stages B and C prostate carcinoma.

Authors:  J G Müller; S Demel; M P Wirth; A Manseck; H G Frohmüller; H A Müller
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

2.  Genomic deletion of chromosome 12p is an independent prognostic marker in prostate cancer.

Authors:  Martina Kluth; Ramin Ahrary; Claudia Hube-Magg; Malik Ahmed; Heinke Volta; Catina Schwemin; Stefan Steurer; Corinna Wittmer; Waldemar Wilczak; Eike Burandt; Till Krech; Meike Adam; Uwe Michl; Hans Heinzer; Georg Salomon; Markus Graefen; Christina Koop; Sarah Minner; Ronald Simon; Guido Sauter; Thorsten Schlomm
Journal:  Oncotarget       Date:  2015-09-29

3.  Histopathological grading and DNA ploidy as prognostic markers in metastatic prostatic cancer.

Authors:  T Jørgensen; K Yogesan; F Skjørten; A Berner; K J Tveter; H E Danielsen
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.